Hydrocortisone liquid - Eton Pharmaceuticals
Alternative Names: ET-400; ET-800; Hydrocortisone vial; KHINDIVILatest Information Update: 02 Jun 2025
At a glance
- Originator Crossject
- Developer Eton Pharmaceuticals
- Class Alcohols; Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Registered Adrenal insufficiency
Most Recent Events
- 28 May 2025 Registered for Adrenal insufficiency (In children, In adolescents, In adults) in USA (PO)
- 28 May 2025 Eton Pharmaceuticals plans to launch hydrocortisone liquid in adrenal insufficiency in second week of June 2025
- 25 Mar 2025 Eton Pharmaceuticals acquires US and Canadian rights to Hydrocortisone liquid from Crossject